1	AKBAR SMF, YOSHIDA O, HIASA Y. Immune therapies against chronic hepatitis B[J]. J Gastroenterol, 2022, 57(8): 517-528 本文引用 [1]

2	张维璐, 吉兆华, 付婷, 等. 中国2007—2016年59岁以下普通人群HBsAg阳性率的Meta分析[J]. 中华流行病学杂志, 2017, 38(9): 1278-1284. 本文引用 [1]

3	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 现代消化及介入诊疗, 2006, 11(4): 245-255. 本文引用 [2]

4	李宽, 宁会彬, 尚佳. 乙型肝炎病毒感染与肝癌临床研究最新进展[J]. 西南医科大学学报, 2021, 44(6): 607-611. 本文引用 [1]

5	CHOI WM, KIM GA, CHOI J, et al. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B[J]. J Clin Invest, 2022, 132(10): e154833.

6	WANG J, ZHU L, ZHANG S, et al. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA[J]. Emerg Microbes Infect, 2024, 13(1): 2339944. 本文引用 [1]

7	LOK AS, ZOULIM F, DUSHEIKO G, et al. Hepatitis B cure: From discovery to regulatory approval[J]. J Hepatol, 2017, 67(4): 847-861. 本文引用 [1]

8	CORNBERG M, LOK ASF, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference[J]. J Hepatol, 2020, 72(3): 539-557. 本文引用 [1]

9	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27(12): 938-961. 本文引用 [1]

10	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023. 41(1): 3-28. 本文引用 [1]

11	YOU H, WANG F, LI T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. J Clin Transl Hepatol, 2023, 11(6): 1425-1442. 本文引用 [3]

12	林顺伟, 周舒冬, 郜艳晖, 等. 慢性乙型肝炎患者抗病毒治疗的依从性分析[J]. 临床肝胆病杂志, 2020, 36(3): 532-535. 本文引用 [1]

13	FAN R, YIN X, LIU Z, et al. A hepatitis B-free generation in China: from dream to reality[J]. Lancet Infect Dis, 2016, 16(10): 1103-1105. 本文引用 [1]

14	宋晓静, 郑燕, 陶娟, 等. 规范抗乙肝病毒治疗与肝癌术后肿瘤复发的关系[J]. 西南医科大学学报, 2023, 46(1): 37-40. 本文引用 [1]

15	石宇婧, 张大志. 早期积极抗HBV治疗有益于降低肝癌发生风险及HBV特异性T淋巴细胞免疫功能重建[J]. 中华肝脏病杂志, 2023, 31(3): 314-315.

16	闻朝建, 方向春, 嵇惠宇, 等. 术前恩替卡韦抗病毒治疗对乙肝相关肝癌患者微血管侵犯发生的影响[J]. 临床肿瘤学杂志, 2022, 27(10): 917-921. 本文引用 [1]

17	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. 本文引用 [1]

18	YIP TCF, WONG GLH, CHAN HLY, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. 本文引用 [1]

19	GUO Y, HAN J, ZHANG Y, et al. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation[J]. Front Cell Infect Microbiol, 2023, 13: 1120300. 本文引用 [3]

20	LI MH, YI W, ZHANG L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J]. J Viral Hepat, 2019, 26(): 32-41. 本文引用 [1] 摘要 Suppl 1

21	YE J, CHEN J. Interferon and hepatitis B: current and future perspectives[J]. Front Immunol, 2021, 12: 733364. 本文引用 [2]

22	LIANG KH, HSU CW, CHANG ML, et al. Peginterferon is superior to Nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B[J]. J Infect Dis, 2016, 213(6): 966-974. 本文引用 [1]

23

WU FP, YANG Y, LI M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL: an observational study[J]. World J Gastroenterol, 2020, 26(13): 1525-1539. 本文引用 [1]

24	PENG Y, ZHU W, FU J, et al. Conversion Strategies in chronic hepatitis B patients with Low-level Viremia: A Multi-Center Study[EB/OL]. [2024-4-1]. https://mp.weixin.qq.com/s/JtGT7PCWmxdSNTJs9qm8Rw 本文引用 [1]

25	吴丽丽, 高志良. 抗病毒治疗后慢性乙型肝炎HBsAg阴转的预测因子[J]. 中华肝脏病杂志, 2024, 32(2): 186-192. 本文引用 [1]

26	LI YY, TANG LB, GUO L, et al. CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection[J]. J Hepatol, 2020, 72(3): 420-430.

27	SCHUCH A, SALIMI ALIZEI E, HEIM K, et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load[J]. Gut, 2019, 68(5): 905-915.

28	WANG HL, LUO H, WAN X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1): 45-56. 本文引用 [1]

29	XIONG SE, ZHU D, LIANG BY, et al. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss[J]. eBioMedicine, 2021, 69: 103464. 本文引用 [1]

30	GARCIA LM, LENS S, PALLETT LJ, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients[J]. J Hepatol, 2021, 74(5): 1064-1074. 本文引用 [1]

31	ZHANG JW, LAI RM, WANG LF, et al. Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B[J]. J Hepatol, 2024, 81(6)：960-970. 本文引用 [1]

32	WISHNIE AJ, CHWAT-EDELSTEIN T, ATTAWAY M, et al. BCR affinity influences T-B interactions and B cell development in secondary lymphoid organs[J]. Front Immunol, 2021, 12: 703918. 本文引用 [1]

33	NING Q, HAN MF, SUN YT, et al. Switching from entecavir to PegIFN Alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)[J]. J Hepatol, 2014, 61(4): 777-784. 本文引用 [1]

34	HE LT, YE XG, ZHOU XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients[J]. World J Gastroenterol, 2016, 22(46): 10210-10218. 本文引用 [1]

35	XIE C, XIE DY, FU L, et al. SAT369 functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest project in China)-3.5 years data update[J]. J Hepatol, 2022, 77: S838. 本文引用 [1]

36	MO ZS， RUAN QF， XUE XL，et al. The interim analysis of E-Cure study for inactive hepatitis B surface antigen carriers in China[EB/OL]. [2024-4-1]. https://mp.weixin.qq.com/s/zApE-2WJoCiPADJCi5zhYQ 本文引用 [1]

37	孔媛媛, 刘晓清, 尤红, 等. 乙型肝炎创新药物临床试验设计的方法学考量[J]. 中华肝脏病杂志, 2020, 28(8): 658-661. 本文引用 [1]

38	GANE E, LIM YS, KIM JB, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials[J]. J Hepatol, 2023, 79(4): 924-932. 本文引用 [1]

39	REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558. 本文引用 [1]

40	VAILLANT A. Efficacy and safety of bepirovirsen in hepatitis B[J]. N Engl J Med, 2023, 388(12): 1146-1147.

41	LEMPP FA, VOLZ T, CAMERONI E, et al. Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice[J]. J Hepatol, 2023, 79(5): 1129-1138. 本文引用 [1]

42	陈莎, 赵连晖, 单姗, 等. 治愈慢性乙型肝炎新药临床试验方案的系统评价[J]. 中华肝脏病杂志, 2020, 28(8): 662-666. 本文引用 [1]

43	CAREY I, GERSCH J, WANG B, et al. Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e Antigen-negative chronic hepatitis B patients suppressed on Nucleos(T)ide analogue therapy[J]. Hepatology, 2020, 72(1): 42-57. 本文引用 [1]

44	XIA YC, GUO HT. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential[J]. Antivir Res, 2020, 180: 104824. 本文引用 [1]

45	HUANG D, WU D, WANG P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB[J]. J Hepatol, 2022, 77(1): 42-54. 本文引用 [1]

46	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 中华临床感染病杂志, 2019, 12(4): 241-252. 本文引用 [1]

47	FAN H, LIN L, JIA S, et al. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B[J]. J Viral Hepat, 2019, 26(): 77-84. 本文引用 [1] 摘要 Suppl 1

48	LIU Y, LI H, YAN X, et al. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B[J]. J Viral Hepat, 2019, 26(): 69-76. 本文引用 [1] 摘要 Suppl 1

49	LU J, ZHANG S, LIU Y, et al. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA[J]. Liver Int, 2015, 35(6): 1692-1699. 本文引用 [1]

50	HU P, SHANG J, ZHANG W, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study[J]. J Clin Transl Hepatol, 2018, 6(1): 25-34. 本文引用 [1]

51	闫一杰, 王晓晓, 曹振环, 等. 48周HBsAg低水平的HBeAg阴性慢性乙型肝炎患者是获得HBsAg清除的优势人群[J]. 中华肝脏病杂志, 2018, 26(11): 813-818. 本文引用 [1]